We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eschenbach's Selection 'Troubling,'Claim Various Stakeholders
Eschenbach's Selection 'Troubling,'Claim Various Stakeholders
September 30, 2005
The Bush administration’s choice of Andrew von Eschenbach to be the interim FDA commissioner has raised concerns among various stakeholders, who say his role as director of the National Cancer Institute (NCI) and his alleged decision to continue to run that group shows a lack of the necessary objectivity and dedication needed to run the FDA.